- Profitability achieved for the second consecutive quarter.
- Cash flow positive for the fourth consecutive quarter.
- Total revenues and net income for the nine-month period ended September 30, 2010 were EUR 18.44 (US$25.17) million and EUR 3.44 (US$4.69) million, respectively.
- Total revenues increased 201% to EUR 18.44 million, compared with EUR 6.12 million.
- Operating costs and expenses, which include restructuring charges of EUR 0.95 million, were EUR 14.83 million, compared with EUR 10.66 million.
- Research and development expenses, which are included in operating costs and expenses, were EUR 4.63 million, compared with EUR 2.66 million. 2009 research and development expenses were net of EUR 0.76 million of government grants in the form of a tax credit, accrued as a reduction of expenses. Excluding such grants, 2009 research and development expenses would have been EUR 3.42 million.
- Operating income/(loss) was EUR 3.62 million, compared with EUR (4.54) million.
- Net income/(loss) was EUR 3.44 million, compared with EUR (4.48) million.
- Basic and diluted net income/(loss) per share was EUR 0.23, compared with EUR (0.30) per share.
- Total revenues were EUR 5.91 million, compared with EUR 2.50 million. Product sales for the three-month period ended September 30, 2010 increased 97% to EUR 4.85 million compared to EUR 2.46 million in the third quarter of 2009. Defibrotide net sales through named-patient and cost recovery programs were EUR 3.36 million, or 69% of total product sales, an increase of 142% compared to EUR 1.39 million for the same period in 2009. Sales of the Company's API amounted to 1.49 million, or 31% of total product sales, an increase of 39% compared to EUR 1.07 million for the same period in 2009.
- Operating costs and expenses were EUR 4.36 million, compared with EUR 3.49 million.
- Research and development expenses, which are included in operating costs and expenses, were EUR 1.17 million, compared with EUR 0.85 million.
- Operating income/(loss) was EUR 1.55 million, compared with EUR (0.99) million.
- Net income/(loss) was EUR 1.12 million, compared with EUR (1.02) million.
- Basic and diluted net income/(loss) per share was EUR 0.08, compared with EUR (0.07) per share.
Operating ResultsProduct sales for the nine-month period ended September 30, 2010 were EUR 14.87 million compared to EUR 5.99 million for the same period in 2009, more than doubling. The increase was primarily due to the distribution of Defibrotide through the named-patient and cost recovery programs, which were initiated in April and October 2009, respectively. For the nine-month period ended September 30, 2010, named-patient and cost recovery programs sales amounted to EUR 9.96 million (or 67% of total product sales), which are net of EUR 1.59 million in service fees, compared to EUR 2.43 million, net of related service fees, for the same period in 2009. API revenues increased to EUR 4.91 million (or 33% of total product sales) for the nine-month period ended September 30, 2010 from EUR 3.56 million for the same period in 2009, reflecting the increase of 1.35 million or 38%. Other revenues were EUR 3.57 million for the nine-month-period ended September 30, 2010 compared to EUR 0.13 million for the same period in 2009. Fluctuation versus the prior period is primarily attributable to an increase in activities that were reimbursed from Sigma-Tau under a cost sharing arrangement with the Company, which amounted to EUR 0.86 million and EUR 0.06 million as of September 30, 2010 and 2009, respectively, and a ratable recognition of EUR 2.56 million ($3.50 million) of the EUR 5.11 million ($7.0 million) up-front payment made by Sigma-Tau in connection with the amendment of the existing license and supply agreement with the Company. The up-front payment is being recognized ratably through the second quarter of 2011, which is when the Company expects to file an NDA for Defibrotide. Cost of goods sold was EUR 4.29 million for the nine-month period ended September 30, 2010 compared to EUR 3.13 million for the same period in 2009. Cost of goods sold as a percentage of product sales was 29% for the nine-month period ended September 30, 2010 compared to 52% for the same period in 2009. The percentage decrease is primarily due to higher margins on Defibrotide sold through the named-patient and cost recovery programs.
The Company incurred research and development expenses of EUR 4.63 million for the nine-month period ended September 30, 2010 compared to EUR 2.66 million for the same period in 2009. 2009 research and development expenses were net of EUR 0.76 million of government grants in the form of a tax credit, accrued as a reduction of expenses. Research and development expenses were primarily for the development of Defibrotide to treat and prevent VOD. The increase from the comparable period in 2009 was primarily due to the completion of a technology transfer and preclinical and safety studies that are required for regulatory filings.General and administrative expenses were EUR 4.07 million for the nine-month period ended September 30, 2010 compared to EUR 3.96 million for the same period in 2009. 2010 and 2009 general and administrative expenses reflect a reduction of a reserve for doubtful accounts for EUR 0.25 million and EUR 0.41 million, respectively, due to the deemed payment of accounts receivable through the elimination of the same amount of account payables due to the same counterparty. The slight increase in general and administrative expenses was primarily due to an increase in stock-based compensation expenses. Corporate restructuring charges resulting from a strategic decision to close the Company's New York office amounted to EUR 0.95 million for the nine-month period ended September 30, 2010. The Company has not accounted for certain corporate taxes in Italy due to the existing prior-year operating losses. Such losses have resulted in a tax benefit amounting to EUR 15.45 million. This amount will be carried forward to off-set future corporate tax payments, if any. The Company is currently evaluating the effects of the deferred tax accounting on its financial statements in light of the Company's long term development plans. Current tax expense amounting to EUR 0.22 million represent an Italian state tax on productive activities at a rate of 3.9%.
Our net income was EUR 3.44 million for the nine-month period ended September 30, 2010, compared to a net loss of EUR (4.48) million for the comparable period in 2009. The difference was primarily due to higher sales and margin on Defibrotide sold through the named-patient and cost recovery programs and an increase in other income and revenues (including the ratable recognition as revenue of a portion of the up-front payment made by Sigma-Tau in connection with the amendment of the existing license and supply agreement with the Company), offset by an increase in research and development expenses, general and administrative expenses and restructuring charges.About VOD Veno-occlusive disease is a potentially life-threatening condition, which typically occurs as a significant complication of stem cell transplantation. Certain high-dose conditioning regimens used as part of stem cell transplant (SCT) can damage the lining cells of hepatic blood vessels and so result in VOD, a blockage of the small veins of the liver that leads to liver failure and can result in significant dysfunction in other organs such as the kidneys and lungs (so-called severe VOD). SCT is a frequently used treatment modality following high-dose chemotherapy and radiation therapy for hematologic cancers and other conditions in both adults and children. There is currently no approved agent for the treatment or prevention of VOD in the U.S. or the EU. About Gentium Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD and Fast Track Designation by the U.S. FDA to treat VOD.
Cautionary Note Regarding Forward-Looking StatementsThis press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results, including with respect to any financial forecast or the possibility of any future regulatory approval, may differ materially from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20-F filed with the Securities and Exchange Commission under the caption "Risk Factors."
|(Amounts in thousands of Euro, except share and per share data)|
|December, 31||September 30,|
|Cash and cash equivalents||1,392||9,290|
|Accounts receivable from related parties, net of allowance of €1,099 and €849 as of December 31, 2009 and September 30, 2010, respectively||501||501|
|Prepaid expenses and other current assets||1,431||663|
|Total Current Assets||8,088||15,831|
|Property, manufacturing facility and equipment, at cost||21,262||21,321|
|Less: Accumulated depreciation||11,545||12,509|
|Property, manufacturing facility and equipment, net||9,717||8,812|
|Intangible assets, net of amortization||76||62|
|Available for sale securities||263||263|
|Other non-current assets||23||22|
|LIABILITIES AND SHAREHOLDERS' EQUITY|
|Accounts payables to related parties||286||289|
|Accrued expenses and other current liabilities||1,907||1,231|
|Current portion of capital lease obligations||67||69|
|Current maturities of long-term debt||408||1,209|
|Total Current Liabilities||7,047||10,386|
|Long-term debt, net of current maturities||3,098||2,109|
|Capital lease obligations||91||39|
|Share capital (no par value; 18,302,617 shares authorized; 14,956,317 shares issued and outstanding at December 31, 2009 and September 30, 2010)||106,962||108,141|
|Total Shareholders' Equity||7,330||11,949|
|Total Liabilities and Shareholders' Equity||18,167||24,990|
|Statements of Operations|
|(Unaudited, amounts in thousands of Euro except share and per share data)|
|Three months ended||Nine months ended|
|September 30,||September 30,|
|Product sales to third parties||2,461||4,850||5,793||14,870|
|Product sales to related party||--||--||195||--|
|Total product sales||2,461||4,850||5,988||14,870|
|Other revenues from related party||22||946||63||3,422|
|Operating costs and expenses:|
|Cost of goods sold||1,130||1,420||3,130||4,285|
|Research and development||849||1,174||2,657||4,625|
|General and administrative||1,197||1,468||3,958||4,074|
|Charges from related parties||69||69||210||218|
|Depreciation and amortization||241||224||706||671|
|Foreign currency exchange gain/(loss), net||(6)||(191)||163||104|
|Interest expense, net||(26)||(23)||(98)||(64)|
|Income/(Loss) before income tax expense||(1,023)||1,339||(4,477)||3,656|
|Provision for income taxes:|
|Income tax expense||--||(216)||--||(216)|
|Shares used in computing net income/(loss) per share, basic and diluted||14,956,317||14,956,317||14,956,317||14,956,317|
|Net income/(loss) per share:|
|Basic and diluted net income/(loss) per share||(0.07)||0.08||(0.30)||0.23|
|Statements of Cash Flows|
|(Unaudited, amounts in thousands of Euro except share and share per data)|
|For the Nine Months Ended September 30,|
|Cash Flows From Operating Activities:|
|Adjustments to reconcile net income/(loss) to net cash provided by/(used in) operating activities:|
|Write-down of inventory||101||143|
|Unrealized foreign exchange gain||(248)||(32)|
|Depreciation and amortization||970||983|
|Stock based compensation||1,057||1,179|
|Loss on fixed asset disposal||--||20|
|Release of allowance for doubtful accounts||(413)||(250)|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other assets||17||769|
|Accounts payable and accrued expenses||(1,053)||102|
|Net cash provided by/(used in) operating activities||(5,807)||8,192|
|Cash Flows From Investing Activities|
|Acquisition of Crinos Assets||(4,000)||--|
|Net cash used in investing activities||(4,248)||(84)|
|Cash Flows From Financing Activities:|
|Repayment of long-term debt||(903)||(188)|
|Payment of capital lease obligation||(48)||(50)|
|Net cash used in financing activities||(951)||(238)|
|Increase/(Decrease) in cash and cash equivalents||(11,006)||7,870|
|Effect of exchange rate on cash and cash equivalents||219||28|
|Cash and cash equivalents, beginning of period||11,491||1,392|
|Cash and cash equivalents, end of period||704||9,290|
CONTACT: Gentium S.p.A. Salvatore Calabrese, Senior Vice President, Finance +39 031-385-287 email@example.com The Trout Group Marcy Nanus +1 646-378-2927 firstname.lastname@example.org